New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?

Arterial hypertension is the most prevalent controllable disease world-wide. Yet, we still need to further improve blood pressure control, deal with resistant hypertension, and we hope to reduce risk “beyond blood pressure.” The number of candidate molecules aspiring for these aims is constantly declining. The new possible approaches to combat high blood pressure include neprilysin/neutral endopeptidase (NEP) inhibition, particularly when combined with an angiotensin receptor blockade (such as the ARNI, LCZ696), phosphodiesterase 5 (PDE5) inhibition (KD027/Slx-2101), natriuretic agents (PL3994), or a long-lasting vasointestinal peptide (VIP) analogue (PB1046). Other options exploit the protective arm of the renin-angiotensin-aldosterone system by stimulating the angiotensin AT2 receptor (compound 21), the Mas receptor (AVE-0991), or the angiotensin converting enzyme 2. Finally, we review the possibilities how to optimize the use of the available treatment options by using drug combinations or by tailoring therapy to each patient’s angiotensin peptide profile.

• Publication year

  2015

• Venue

  Current Hypertension Reports

• Publication date

  2015-04-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11906-015-0557-xPMID 25893478PMCID 4412646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy

  2015cited by this paper
• Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison.

  2015cited by this paper
• Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels.

  2015cited by this paper
• Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.

  2015cited by this paper
• The Protective Arms of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

  2015cited by this paper
• Effects of PDE type 5 inhibitors on Left Ventricular Diastolic Dysfunction in Resistant Hypertension

  2015cited by this paper
• Inflammation and Hypertension: New Understandings and Potential Therapeutic Targets

  2014cited by this paper
• A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction

  2014cited by this paper
• Treatment with Angiotensin-(1–7) reduces inflammation in carotid atherosclerotic plaques

  2014cited by this paper
• An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats.

  2014cited by this paper
• Treatment of Hypertension and Metabolic Syndrome: Lowering Blood Pressure Is Not Enough for Organ Protection, New Approach-Arterial Destiffening

  2014cited by this paper
• Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study

  2014cited by this paper
• Angiotensin-Converting Enzyme 2–Independent Action of Presumed Angiotensin-Converting Enzyme 2 Activators: Studies In Vivo, Ex Vivo, and In Vitro

  2014cited by this paper
• Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor &bgr;1 in the Rat Heart

  2014cited by this paper
• Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study

  2014cited by this paper
• Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2

  2014cited by this paper
• Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension

  2014cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• AT2 Receptor Activation Induces Natriuresis and Lowers Blood Pressure

  2014cited by this paper
• Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice.

  2014cited by this paper
• Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension

  2014cited by this paper
• A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

  2014cited by this paper
• Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

  2014cited by this paper
• Complete Renin–Angiotensin–Aldosterone System (RAAS) Blockade in High-Risk Patients: Recent Insights From Renin Blockade Studies

  2013cited by this paper
• Oral administration of angiotensin-(1–7) ameliorates type 2 diabetes in rats

  2013cited by this paper
• Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension

  2013cited by this paper
• 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

  2013cited by this paper
• Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy

  2013cited by this paper
• Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects

  2013cited by this paper
• Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope?

  2013cited by this paper
• New Renin Inhibitor VTP-27999 Alters Renin Immunoreactivity and Does Not Unfold Prorenin

  2013cited by this paper
• Proximal Tubule Angiotensin AT2 Receptors Mediate an Anti-Inflammatory Response via Interleukin-10: Role in Renoprotection in Obese Rats

  2013cited by this paper
• The effect of cilostazol on right heart function and pulmonary pressure.

  2013cited by this paper
• Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome

  2013cited by this paper
• Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats.

  2013cited by this paper
• Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension

  2013cited by this paper
• EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

  2013cited by this paper
• In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.

  2013cited by this paper
• Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.

  2013cited by this paper
• Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

  2013cited by this paper
• THE OBESITY PARADOX: THE IMPORTANCE FOR LONG-TERM OUTCOMES IN NON-ST-ELEVATION MYOCARDIAL INFARCTION – THE CRUSADE EXPERIENCE

  2013cited by this paper
• AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression.

  2013cited by this paper
• Beneficial Effects of the Activation of the Angiotensin-(1–7) Mas Receptor in a Murine Model of Adriamycin-Induced Nephropathy

  2013cited by this paper
• VASOMERA™, A NOVEL VPAC2-SELECTIVE VASOACTIVE INTESTINAL PEPTIDE AGONIST, ENHANCES CONTRACTILITY AND DECREASES MYOCARDIAL DEMAND IN DOGS WITH BOTH NORMAL HEARTS AND WITH PACING-INDUCED DILATED CARDIOMYOPATHY

  2013cited by this paper
• Direct Angiotensin II Type 2 Receptor Stimulation in N&ohgr;-Nitro-L-Arginine-Methyl Ester–Induced Hypertension: The Effect on Pulse Wave Velocity and Aortic Remodeling

  2012cited by this paper
• Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

  2012cited by this paper
• Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats

  2012cited by this paper
• Key advances in antihypertensive treatment

  2012cited by this paper
• Bristol Myers-Squibb

  2012cited by this paper
• New therapeutic pathways in the RAS

  2012cited by this paper
• Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA–salt-induced hypertension in rats

  2012cited by this paper
• Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury

  2012cited by this paper
• AT2 receptor agonists: hypertension and beyond

  2012cited by this paper
• Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.

  2012cited by this paper
• Differential pharmacology and benefit/risk of azilsartan compared to other sartans

  2012cited by this paper
• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

  2012cited by this paper
• Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension

  2011cited by this paper
• Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial

  2011cited by this paper
• Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival

  2011cited by this paper
• Emerging drugs which target the renin–angiotensin–aldosterone system

  2011cited by this paper
• Recombinant Human Angiotensin-Converting Enzyme 2 as a New Renin-Angiotensin System Peptidase for Heart Failure Therapy

  2011cited by this paper
• Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure.

  2011cited by this paper
• Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker

  2011cited by this paper
• Angiotensin‐converting enzyme 2 activation protects against hypertension‐induced cardiac fibrosis involving extracellular signal‐regulated kinases

  2011cited by this paper
• The functional genomics of guanylyl cyclase/natriuretic peptide receptor‐A: Perspectives and paradigms

  2011cited by this paper
• Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial

  2010cited by this paper
• Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor

  2010cited by this paper
• Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor &kgr;B

  2010cited by this paper
• Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism

  2010cited by this paper
• Novel therapeutic targets for hypertension

  2010cited by this paper
• Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction

  2010cited by this paper
• Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

  2010cited by this paper
• Identification of Noncytotoxic and IL-10–Producing CD8+AT2R+ T Cell Population in Response to Ischemic Heart Injury

  2010cited by this paper
• Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage

  2009cited by this paper
• Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

  2009cited by this paper
• The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.

  2009cited by this paper
• A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.

  2009cited by this paper
• Phase IIa Study of the NPR-A Agonist, PL-3994, in Healthy Adult Volunteers with Controlled Hypertension

  2009cited by this paper
• Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model.

  2008cited by this paper
• Novel Antihypertensive Agents Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2

  2008cited by this paper
• Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.

  2008cited by this paper
• Transgenic Angiotensin-Converting Enzyme 2 Overexpression in Vessels of SHRSP Rats Reduces Blood Pressure and Improves Endothelial Function

  2008cited by this paper
• Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?

  2008cited by this paper
• The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

  2008cited by this paper
• Phase I Study of the Novel A-Type Natriuretic Receptor Agonist, PL-3994, in Healthy Volunteers

  2008cited by this paper
• 2013 ESH/ESC Guidelines for the management of arterial hypertension

  2007influential reference
• Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension

  2007cited by this paper
• Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension

  2007cited by this paper
• Low-dose spironolactone in the management of resistant hypertension: a surveillance study

  2007cited by this paper
• Selective and mixed endothelin receptor antagonism in cardiovascular disease.

  2007cited by this paper
• Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.

  2007cited by this paper
• Role of Endothelins in Hypertension

  2007cited by this paper
• Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans

  2006cited by this paper

• Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting

  2026cites this paper
• An Overview of Hypertension: Pathophysiology, Risk Factors, and Modern Management.

  2025cites this paper
• Analysis of modifying factors for ACE2 to work effectively

  2025cites this paper
• An emerging view on vascular fibrosis molecular mediators and relevant disorders: from bench to bed

  2023cites this paper
• Neuroimmune Interactions in the Lung.

  2023cites this paper
• Theoretical investigation on known renin inhibitors and generation of ligand-based pharmacophore models for hypertension treatment

  2023cites this paper
• Hypertension after kidney transplantation

  2022cites this paper
• Nanoemulsions for the Delivery of Anti-Hypertensive Drugs

  2022cites this paper
• Renin–Angiotensin–Aldosterone System: Friend or Foe—The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions

  2021cites this paper
• Renin-Angiotensin-Aldosterone System

  2021cites this paper
• Update on Angiotensin II Subtype 2 Receptor: Focus on Peptide and Nonpeptide Agonists

  2021cites this paper
• [Endothelium-related and neuro-mediated mechanisms of emphysema development in chronic obstructive pulmonary disease].

  2020cites this paper
• Evaluation of new antihypertensive drugs designed in silico using Thermolysin as a target

  2020cites this paper
• Novel strategies of hypertension management in chronic kidney disease

  2020cites this paper
• Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.

  2019cites this paper
• A BRIEF REVIEW ON ROLE OF NANOCARRIER AS ANTIHYPERTNESIVE AGENTS

  2019influential citation
• Antifibrotic Roles of RAAS Blockers: Update

  2019cites this paper
• A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism

  2019cites this paper
• Investigation of Drug Interaction Potentials and Binding Modes on Direct Renin Inhibitors: A Computational Modeling Studies

  2019cites this paper
• Future pharmacological therapy in hypertension

  2018cites this paper
• Small‐molecule AT2 receptor agonists

  2018cites this paper
• Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis

  2018cites this paper
• Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension

  2018cites this paper
• Gene therapy for hypertension

  2017cites this paper
• Novel approaches for treating hypertension

  2017cites this paper
• Brain renin‐angiotensin system in the pathophysiology of cardiovascular diseases☆

  2017cites this paper
• Nanocarriers as treatment modalities for hypertension

  2017influential citation
• Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.

  2017cites this paper
• Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology

  2016cites this paper
• Étude physiopathologique de l'hypertension artérielle essentielle

  2016cites this paper
• Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

  2016cites this paper
• Pharmacological significance of the interplay between angiotensin receptors: MAS receptors as putative final mediators of the effects elicited by angiotensin AT1 receptors antagonists.

  2015cites this paper
• Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice

  2015cites this paper
• Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders

  2015cites this paper
• Novel approaches for treating hypertension

  year unknowncites this paper
• “Nanocarrier as an Antihypertensive Agent”

  year unknowncites this paper